A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 23, Issue 3, 2005, Pages 143-149

  Winquist, Eric ^a   Moore, Malcolm J ^b   Chi, Kim N ^c   Ernst, D Scott ^d   Hirte, Hal ^e   North, Scott ^f   Powers, Jean ^g   Walsh, Wendy ^g   Boucher, Therese ^h   Patton, Robert ⁱ   Seymour, Lesley ^g  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d TOM BAKER CANCER CENTRE   (Canada)

^e JURAVINSKI CANCER CENTRE   (Canada)

^f CROSS CANCER INSTITUTE   (Canada)

^g Queen's Cancer Research Institute   (Canada)

^h Schering Plough Canada Inc   (Canada)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Bladder neoplasms; Drug therapy; Farnesyltransferase; Lonafarnib

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; CREATININE; LONAFARNIB;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEHYDRATION; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; FLATULENCE; FLU LIKE SYNDROME; FOLLOW UP; GRANULOCYTOPENIA; HEADACHE; HEART ATRIUM FIBRILLATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEARTBURN; HUMAN; INSOMNIA; LEUKOPENIA; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SINUS TACHYCARDIA; SMELLING DISORDER; STOMATITIS; SWEATING; TACHYCARDIA; TASTE DISORDER; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; UROGENITAL TRACT CANCER; VOMITING; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PIPERIDINES; PYRIDINES; URETERAL NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 21144440538     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2004.12.012     Document Type: Article

References (33)

1. J. Downward Targeting RAS signalling pathways in cancer therapy Nat Rev Cancer 3 2003 11 22
2. P. Haluska, G.K. Dy, A.A. Adjei Farnesyl transferase inhibitors as anticancer agents Eur J Cancer 38 2002 1685 1700
3. S. Brandau, A. Bohle Bladder cancer. I. Molecular and genetic basis of carcinogenesis Eur Urol 39 2001 491 497
4. S. Rodenhuis Ras and human tumors Semin Cancer Biol 3 1992 241 247
5. J.E. Dancey Agents targeting ras signaling pathway Curr Pharm Des 8 2002 2259 2267
6. J. Larner, J. Jane, E. Laws A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme Am J Clin Oncol 21 1998 579 583
7. H.H. Bailey, D. Levy, L.S. Harris A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer Eastern Cooperative Oncology Group Study E2E96 Gynecol Oncol 85 2002 464 468
8. G.R. Hudes, C.E. Sazarka, A. Adams Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies Clin Cancer Res 6 2002 3071 3080
9. S.M. Hahn, E.J. Bernhard, W. Regine A phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer Clin Cancer Res 8 2002 1065 1072
10. S.C. Bolick, T.H. Landowski, D. Boulware The farnesyltransferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells Leukemia 17 2003 451 457
11. J. Sun, M.A. Blaskovich, D. Knowles Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I Combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine Cancer Res 59 1999 4919 4926
12. P. Russo, D. Arzani, S. Trombino c-myc down-regulation induces apoptosis in human cancer cell lines exposed to RPR-115135 (C31H29NO4), a non-peptidomimetic farnesyltransferase inhibitor J Pharmacol Exp Ther 304 2003 37 47
13. F. Megnin-Chanet, F. Lavelle, V. Favaudon The farnesyl transferase inhibitor RPR-130401 does not alter radiation susceptibility in human tumor cells with a K-Ras mutation in spite of large changes in ploidy and lamin B distribution BMC Pharmacol 2 2002 2
14. M. Liu, M.S. Bryant, J. Chen Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice Cancer Res 58 1998 4947 4956
15. A.A. Adjei, C. Erlichman, J.N. Davis A phase I trial of the farnesyl transferase inhibitor SCH66336 evidence for biological and clinical activity Cancer Res 60 2000 1871 1877
16. H.I. Hurwitz, O.M. Colvin, W.P. Petros Phase I and pharmacokinetic study of SCH66336, a novel FPTI, using a 2-week on, 2-week off schedule [abstract] Proc Am Soc Clin Oncol 18 1999 156a
17. F.A. Eskens, A. Awada, D.L. Cutler Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors J Clin Oncol 19 2001 1167 1175
18. A. Awada, F.A. Eskens, M. Piccart Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours Eur J Cancer 38 2002 2272 2278
19. National Cancer Institute. SEER Cancer Statistics Review, 1975-2000. Available at: http://seer.cancer.gov/csr/1975_2000/results_single/sect_01_table. 01.pdf. Accessed January 6, 2005.
20. H. von der Maase, S.W. Hansen, J.T. Roberts Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer Results of a large, randomized multicenter phase III study J Clin Oncol 18 2000 3068 3077
21. R. Dreicer, D.M. Gustin, W.A. See Paclitaxel in advanced urothelial carcinoma Its role in patients with renal insufficiency and as salvage therapy J Urol 156 1996 1606 1608
22. A.A. Meluch, F.A. Greco, H.A. Burris Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract A phase II trial of the Minnie Pearl Cancer Research Network J Clin Oncol 15 19 2001 3018 3024
23. J. Bellmunt, J. Cos, R. Cleries Feasibility trial of methotrexate- paclitaxel as a second line therapy in advanced urothelial cancer Cancer Invest 20 2003 673 685
24. T.F. Orntoft, H. Wolf Molecular alterations in bladder cancer Urol Res 26 1998 223 233
25. M.A. Knowles Molecular genetics of bladder cancer Br J Urol 75 1995 57 66
26. D. Vageli, H. Kiaris, D. Delakas Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder tumors Cancer Lett 107 1996 241 247
27. T. Petit, E. Izbicka, R.A. Lawrence Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units Ann Oncol 10 1999 449 453
28. http://ctep.info.nih.gov/reporting/index.html. Accessed January 6, 2004.
29. P. Therasse, S.G. Arbuck, E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
30. B. Freidlin, J. Dancey, E.L. Korn, B. Zee Multinomial phase II trial designs J Clin Oncol 20 2002 599
31. E.L. Kaplan, P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
32. E. Wang, W.W. Johnson The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2 Exp Chemother 49 2003 303 308
33. A. Nakajima, T. Tauchi, M. Sumi Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells Mol Cancer Ther 2 2003 219 224